Rapid-acting insulin secretagogues: A clinical need?

Experimental and Clinical Endocrinology and Diabetes

Volumn 107, Issue , 1999, Pages S115-S119

  Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

hypoglycaemia; insulin secretagogues; suiphonylureas; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; SULFONYLUREA DERIVATIVE;

BODY WEIGHT; GLUCOSE BLOOD LEVEL; HUMAN; KINETICS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; SECRETION;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; SULFONYLUREA COMPOUNDS;

EID: 0032613269     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1212164     Document Type: Article

References (20)

1. Alberti KGMM, Gries FA, Jervell J, Krans HMJ, for the European NIDDM Policy Group: A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM). Diabetic Med 11: 899–909, 1994
2. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS: Defective glucose regulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 316: 1376–1383, 1987
3. Asplund K, Wilholm B-E, Lithner F: Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24: 412–417, 1983
4. Asplund K, Wiholm B-E, Lundman B: Severe hypoglycaemia during treatment with glipizide. Diabet Med 8: 726–731, 1991
5. Balkau B, Eschwège E, Papoz L, Richard J-L, Claude J-R, Warnet J-M, Ducimetière P: Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 307: 295–299, 1993
6. Groop L, Groop P-H, Stenman S, Saloranta C, Tötterman K-J, Fyhrquist F, Melander A: Comparison of the pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 10: 671–678, 1987
7. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39: 1577–1583, 1996
8. Home PD, Ahmed ABE: Insulin therapy. In: Marshall SM, Home PD, Rizza RA (eds.). The Diabetes Annual 11. Pp. 213–230, Elsevier, Amsterdam, 1998
9. Kruszynska YT, Home PD: Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metabol 14: 437–442, 1988
10. Lager I, Attvall S, Blöhme G, Smith U: Altered recognition of hypoglycaemia symptoms in Type 1 diabetes during intensified control with continuous subcutaneous insulin infusion. Diabet Med 3: 322–325, 1986
11. Lebovitz HE, Melander A: Sulphonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA (eds.). International textbook of diabetes mellitus, Second Edition. pp. 817–840, John Wiley, Chichester, 1997
12. Mitrakou A, Kelley D, Mokan M, Veneman T; Pangburn T; Reilly J; Gerich J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22–29, 1992
13. Owens DR, Luzio SD, Coates PA: Insulin secretion and insulin sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med 13: S19-S24, 1996
14. Phillips DI, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose or insulin measurements during an oral glucose tolerance test with specific measurements of insulin secretion and insulin resistance. Diabet Med 11: 286–292, 1994
15. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC: Natural history of pancreatic islet B-cell function in Type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med 5: 46–51, 1988
16. Tchobroutsky G: Relation of diabetic control to development of microvascular complications. Diabetologia 15: 143–152, 1978
17. Tronier B, Marbury TC, Damsbo P, Windfeld K: A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well-controlled NIDDM patients [abstract]. Diabetologia 38 (Suppl 1): A752, 1995
18. Tunbridge FKE, Home PD, Murphy M, Alberti KGMM: Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen. Diabetic Med 8: 833–838, 1991
19. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998a
20. UK Prospective Diabetes Study (UKPDS) Group: UK Prospective Diabetes Study 26: suiphonylurea failure in non-insulin-dependent diabetic patients over 6 years. Diabet Med 15: 297–303, 1998b